TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04010825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis intervention focused on the emotional dimension of the dyspnea
Description: Individual hypnosis sessions will be for 1 hour. Each hypnosis session will be standardized and evaluated using a script and an observation grid ( Visual Analogic Scale comfort, patient's hypnotic state...) written in collaboration with experts from Institut Milton Hyland Erickson Toulouse France (IMHETO).
Study: NCT04068623

Intervention type: OTHER
Intervention: Blood sample
Description: Blood samples will be collected at 12 months after radiation therapy and at the time of first metastatic recurrence
Study: NCT04271501

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Melanocyte-Keratinocyte Transplantation and Ultraviolet Lamp (UVB)
Description: Application of melanocytes (aka melanocyte-keratinocyte transplantation procedure or MKTP) to surgically prepared depigmented areas

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RECELL 1:5 and Ultraviolet Lamp (UVB)
Description: Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RECELL 1:10 and Ultraviolet Lamp (UVB)
Description: Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RECELL 1:20 and Ultraviolet Lamp (UVB)
Description: Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation
Study: NCT02418221

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DAOSiN®/ Placebo & ProvokAmin® Ingestion
Description: Proband is randomly assigned Daosin® or the Placebo before provocation with ProvokAmin®

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drawing blood, measuring BP & pulse
Description: Taking of a blood sample and recording of blood pressure \& pulse
Study: NCT01708993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed and Reolysin (and safety run-in)
Description: Pemetrexed: 500 mg/m², IV (10 min) - Day 1 every 3 weeks Reolysin: 4.5 x 10\^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed: 500 mg/m² IV (10 min) - Day 1 every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel and Reolysin
Description: Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks Reolysin: 4.5x10\^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks
Study: NCT00519038

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pathways
Description: Clinical pathways are a methodology for the mutual decision making and organization of care for a well-defined group of patients during a well-defined period with the aim to enhance the quality of care by improving patient outcomes, promoting patient safety, increasing patient satisfaction, and optimizing the use of resources. They are also developed by multi-professional teams

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual care is the current practice actually performed in the hospital
Study: NCT02245906

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control drink
Description: As a control, subjects are asked to consume 300 ml control drinks containing equal amount of total fiber and pectine as Brazilian fruit drink. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brazilian fruit peel flour
Description: In this study, subjects are asked to consume 300 ml beverage drinks contain certain amounts of Brazilian fruit peel flour. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Negative control drink
Description: As a negative control, subjects are asked to consume 300 ml control drinks without containing amount of total fiber and pectine as Brazilian fruit drink. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
Study: NCT02102477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatectomy/Surgery
Description: Radical prostatectomy with or without adjuvant or salvage radiotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy with adjuvant androgen deprivation therapy
Description: Radiotherapy with adjuvant androgen deprivation therapy
Study: NCT00640887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifabutin in combination with efavirenz
Description: Ia. arm 1a:~D4T/3TC/EFV(600mg)+INH/Rifabutin(450 mg OD 4 wks switch to 600 mg OD 4 wks);~Ib. arm 1b:~D4T/3TC/EFV(600mg)+INH/Rifabutin(600 mg OD 4 wks switch to 450 mg OD 4 wks);

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifabutin in combination with nevirapine
Description: IIa. arm 2a:~D4T/3TC/NVP(200mg)+INH/Rifabutin(300 mg OD 4 wks switch to 450 mg OD 4 wks);~IIb. arm 2b :~D4T/3TC/NVP(200mg)+INH/Rifabutin(450 mg OD 4 wks switch to 300 mg OD 4 wks);

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifabutin in combination with lopinavir/ritonavir
Description: IIIa. arm 3a :~D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg TPW 4 wks switch to 150 mg OD 4 wks);~IIIb. arm 3b:~D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg OD 4 wks switch to 150 mg TPW 4 wks).
Study: NCT04431401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim rTMS
Description: The device is made in London,UK
Study: NCT02850653

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PCR : 16S ribosomal DNA and real-time targeted PCR

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PCR : 16S ribosomal DNA and real-time targeted PCR

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Sampling of aqueous humour

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Sampling of aqueous humour
Study: NCT04431401

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magstim rTMS
Description: The device is made in London,UK
Study: NCT01235104

Intervention type: PROCEDURE
Intervention: Total nephrectomy
Description: Total nephrectomy
Study: NCT03074760

Intervention type: DIAGNOSTIC_TEST
Intervention: Adenovirus
Description: Diagnostic test for the presence of the adenovirus in the population groups

Intervention type: DIAGNOSTIC_TEST
Intervention: Adenovirus
Description: Diagnostic test for the presence of the adenovirus in the population groups

Intervention type: DIAGNOSTIC_TEST
Intervention: Rotavirus
Description: Diagnostic test for the presence of the Rotavirus in the population groups

Intervention type: DIAGNOSTIC_TEST
Intervention: Rotavirus
Description: Diagnostic test for the presence of the Rotavirus in the population groups
Study: NCT04257110

Intervention type: DRUG
Group type: OTHER
Intervention: BB-1701
Description: BB-1701 will be administered as an intravenous infusion, every 3 weeks or every 4 weeks or every 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-1701
Description: BB-1701 will be administered as an intravenous infusion, every 3 weeks or every 4 weeks or every 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-1701
Description: BB-1701 will be administered as an intravenous infusion, every 3 weeks or every 4 weeks or every 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-1701
Description: BB-1701 will be administered as an intravenous infusion, every 3 weeks or every 4 weeks or every 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-1701
Description: BB-1701 will be administered as an intravenous infusion, every 3 weeks or every 4 weeks or every 6 weeks.
Study: NCT02757209

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spiromax (budesonide/formoterol)
Description: DuoResp Spiromax 160 (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate), either one inhalation twice a day (morning and evening) or two inhalations twice a day (morning and evening), for 1 week.~Additional 8 weeks in one subgroup
Study: NCT03074760

Intervention type: DIAGNOSTIC_TEST
Intervention: H. pylori
Description: Diagnostic test for the presence of H. pylori infection in the population groups

Intervention type: DIAGNOSTIC_TEST
Intervention: H. pylori
Description: Diagnostic test for the presence of H. pylori infection in the population groups
Study: NCT04354896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxin
Description: The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH 0.4 to 4.6 mU/L, no change to dose; TSH ≥4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
Study: NCT02757209

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spiromax (budesonide/formoterol)
Description: DuoResp Spiromax 160 (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate), either one inhalation twice a day (morning and evening) or two inhalations twice a day (morning and evening), for 1 week.~Additional 8 weeks in one subgroup

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spiromax (budesonide/formoterol)
Description: DuoResp Spiromax 160 (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate), either one inhalation twice a day (morning and evening) or two inhalations twice a day (morning and evening), for 1 week.~Additional 8 weeks in one subgroup

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Turbohaler (budesonide/formoterol)
Description: Turbohaler® (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate)- Symbicort® 160/4.5. Dose of one inhalation twice a day (mornig and evening) or two inhalations twice a day (morning and evening), for 1 week. Additional 8 weeks in one subgroup

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Turbohaler (budesonide/formoterol)
Description: Turbohaler® (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate)- Symbicort® 160/4.5. Dose of one inhalation twice a day (mornig and evening) or two inhalations twice a day (morning and evening), for 1 week. Additional 8 weeks in one subgroup

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Turbohaler (budesonide/formoterol)
Description: Turbohaler® (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate)- Symbicort® 160/4.5. Dose of one inhalation twice a day (mornig and evening) or two inhalations twice a day (morning and evening), for 1 week. Additional 8 weeks in one subgroup

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diskus(50mcg salmeterol &250/500 mcg fluticasone propionate)
Description: Diskus® inhaler(50mcg salmeterol\&250/500mcg fluticasone propionate)-Seretide Diskus 50/250mcg® or 50/500mcg.Dose of 1inhalation twice a day for1 week.Additional 8 weeks in1subgroup

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diskus(50mcg salmeterol &250/500 mcg fluticasone propionate)
Description: Diskus® inhaler(50mcg salmeterol\&250/500mcg fluticasone propionate)-Seretide Diskus 50/250mcg® or 50/500mcg.Dose of 1inhalation twice a day for1 week.Additional 8 weeks in1subgroup

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diskus(50mcg salmeterol &250/500 mcg fluticasone propionate)
Description: Diskus® inhaler(50mcg salmeterol\&250/500mcg fluticasone propionate)-Seretide Diskus 50/250mcg® or 50/500mcg.Dose of 1inhalation twice a day for1 week.Additional 8 weeks in1subgroup
Study: NCT04354896

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.
Study: NCT02026310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glimepiride
Description: on the basis of metformin and glargine, glimepiride is added; with the maximun dose of glimepiride, if the targeted FPG is not reached, glargine dose will be increased.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glargine and metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glargine and metformin
Study: NCT03862326

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: From lying to sitting to active exercises with focus on the pelvic floor
Study: NCT02578862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Study: NCT03862326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: From lying to sitting to active exercises with focus on the pelvic floor

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: From lying to sitting to active exercises with focus on the pelvic floor
Study: NCT03096288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).
Study: NCT02578862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Study: NCT03096288

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).
Study: NCT03645720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plastic cannula
Description: puncture using plastic cannula
Study: NCT02690948

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study: NCT01694914

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: corneal graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: corneal graft
Study: NCT03857854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: treatment group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo group
Study: NCT01795677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolotinib
Description: Ruxolotinib doses calculated with platelets count and P450 cytochrome inhibitor HSCT for patients with donor
Study: NCT01598532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedX Health Phototherapy (light therapy)
Description: The treatment period is 6 weeks (3x per week) for a total of 18 Transcranial LED treatments. Each treatment session is 30 minutes each.
Study: NCT03873116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353 capsules
Description: BCX7353 capsules administered orally once daily
Study: NCT02637960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedovapagon 2 mg
Description: One daily dose of 2 mg fedovapagon for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One daily dose of placebo (matched to fedovapagon) for 12 weeks
Study: NCT03873116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353 capsules
Description: BCX7353 capsules administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching placebo capsules administered orally once daily
Study: NCT00597220

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 (n-3 PUFA)
Description: 1 gram of n-3 PUFA containing DHA and EPA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00458263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatotropin growth hormone recombinant human
Description: daily Sub Cutaneous injections
Study: NCT00702221

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant
Description: Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant given as 3 separate intramuscular injections into the arm, 21 days apart

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CoVaccine HT™ adjuvant
Description: Given as three separate intramuscular injections into the arm, 21 days apart
Study: NCT01698840

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00686413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3480
Description: single dose, oral

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 2-[18F]-F-A85380
Description: Single dose, IV
Study: NCT01773044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alkalinized lidocaine
Description: recevied 0.05 mL/kg lidocaine with bicarbonate ( % 2 lidocaine 5 mL + 1 mL %8,4 NaHCO3+ 4 mL SF)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alkalinized lidocaine
Description: recevied 0.05 mL/kg lidocaine with bicarbonate ( % 2 lidocaine 5 mL + 1 mL %8,4 NaHCO3+ 4 mL SF)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 0.05 mL/kg lidocaine (% 2 lidocaine 5 mL + 5 mL SF),

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for alcalinized lidocaine)
Study: NCT01780506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E/C/F/TDF
Description: 150/150/200/300 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TDF Placebo
Description: Tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E/C/F/TAF Placebo
Description: Tablet administered orally once daily
Study: NCT03013270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic-Resistance-Inspiratory
Description: Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with resistance training at an intensity of 50% of 1 Repetition Maximum (1RM) for quads training and upper limb exercises (elbow flex/shoulder flex/abd) using dumbbells (1-2 kg) (12-15 reps/3sets) for 10 min, combined also with inspiratory muscle training with a flow-resistive loading system at an intensity of 60% of maximal inspiratory pressure/sustained maximal inspiratory pressure (PImax/SPImax) for 20 min (Aerobic (30min) + Resistance (10min) + Inspiratory (20min) = 60 min)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic-Resistance
Description: Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with resistance training at an intensity of 50% of 1RM for quads training, pectoralis m, serratus anterior m, and latissimus dorsi m and upper limb exercises (elbow flex/shoulder flex/abd) using dumbbells (1-2 kg) (12-15 reps/3sets).~(Aerobic (30min) + Resistance (30min) = 60 min)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic-Inspiratory
Description: Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with inspiratory muscle training with a flow-resistive loading system at an intensity of 60% of maximal inspiratory pressure/sustained maximal inspiratory pressure (PImax/SPImax) for 30min (Aerobic (30min) + Inspiratory (30min) = 60 min)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Training
Description: Patients will be submitted to a 12 week, 3 times/week continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with callisthenics progressing to treadmill or bike (at the same intensity) for 30 min (Aerobic training = 60 min)
Study: NCT03543644

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar-sweetened beverage (SSB)
Description: SSBs will be provided to each participant. Participants will be able to choose their SSB of choice from the list in the protocol. They will be instructed to drink their usual SSB intake, study drinks provided, while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-nutritive sweetened beverages (NSB)
Description: NSBs will be provided to each participant. Participants will be be given the NSB equivalent to the usual SSB chosen from the list in the protocol. They will be instructed to replace their usual SSBs with the NSBs while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Water will be provided to each participant. They will be instructed to replace their usual SSBs with the water while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
Study: NCT00448123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Study Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01786733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Study: NCT03032393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-power
Description: Subjects will stand with hands on their hips, elbows pointing out and feet approximately one foot apart (high-power) for 20 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low-power
Description: Subjects will stand with hands and arms wrapping around the torso and feet together (low-power) for 20 seconds.